(Q47409584)

15 January 2018

title

Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer (English)

1 reference

15 January 2018

1 reference

4

Carsten Bokemeyer

1 reference

15 January 2018

author name string

Silas C Martin

1

1 reference

15 January 2018

Dennis D Gagnon

2

1 reference

15 January 2018

Lucy Zhang

3

1 reference

15 January 2018

Marinus Van Marwijk Kooy

5

1 reference

15 January 2018

Ben van Hout

6

1 reference

15 January 2018

publication date

1 January 2003

1 reference

15 January 2018

published in

PharmacoEconomics

1 reference

15 January 2018

volume

21

1 reference

15 January 2018

issue

16

1 reference

15 January 2018

page(s)

1153-1169

1 reference

15 January 2018

https://scigraph.springernature.com/pub.10.2165/00019053-200321160-00002

exact match

0 references

cites work

The impact of hemoglobin levels on treatment outcomes in patients with cancer

1 reference

12 December 2020

Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels

1 reference

12 December 2020

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

1 reference

12 December 2020

Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review

1 reference

12 December 2020

Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin.

1 reference

12 December 2020

The estimation of a preference-based measure of health from the SF-36.

1 reference

12 December 2020

The CE plane: a graphic representation of cost-effectiveness.

1 reference

12 December 2020

Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey

1 reference

12 December 2020

Estimating the costs attributable to a disease with application to ovarian cancer

1 reference

12 December 2020

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Cost of care for cancer in a health maintenance organization

1 reference

12 December 2020

Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia

1 reference

12 December 2020

Estimating medical costs from incomplete follow-up data

1 reference

12 December 2020

Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx

1 reference

12 December 2020

Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy

1 reference

12 December 2020

The death of cost-minimization analysis?

1 reference

12 December 2020

Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia

1 reference

12 December 2020

Factors influencing quality of life in cancer patients: anemia and fatigue.

1 reference

12 December 2020

Costs, effects and C/E-ratios alongside a clinical trial.

1 reference

12 December 2020

Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma

1 reference

12 December 2020

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

1 reference

12 December 2020

Cost effectiveness of treatment options in advanced breast cancer in the UK.

1 reference

12 December 2020

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia

1 reference

12 December 2020

Symptomatology of anemia

1 reference

12 December 2020

The annual cost of blood transfusions in the UK.

1 reference

12 December 2020

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

12 December 2020

The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix

1 reference

12 December 2020

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

1 reference

12 December 2020

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care

1 reference

12 December 2020

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

12 December 2020

Management of anemia in patients receiving chemotherapy

1 reference

12 December 2020

10.2165/00019053-200321160-00002

Identifiers

DOI

1 reference

15 January 2018

Dimensions Publication ID

0 references

1 reference

15 January 2018